[go: up one dir, main page]

PE20181531A1 - Vacuna del virus herpes simple - Google Patents

Vacuna del virus herpes simple

Info

Publication number
PE20181531A1
PE20181531A1 PE2018000600A PE2018000600A PE20181531A1 PE 20181531 A1 PE20181531 A1 PE 20181531A1 PE 2018000600 A PE2018000600 A PE 2018000600A PE 2018000600 A PE2018000600 A PE 2018000600A PE 20181531 A1 PE20181531 A1 PE 20181531A1
Authority
PE
Peru
Prior art keywords
herpes virus
virus vaccine
simple herpes
vaccines
hsv
Prior art date
Application number
PE2018000600A
Other languages
English (en)
Inventor
Giuseppe Ciaramella
Shinu John
Andrew J Bett
Danilo R Casimiro
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of PE20181531A1 publication Critical patent/PE20181531A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La descripcion se relaciona con vacunas de acido ribonucleico (ARN) de virus del herpes simple (VHS), asi como a metodos para utilizar las vacunas y a composiciones que comprenden las vacunas
PE2018000600A 2015-10-22 2016-10-21 Vacuna del virus herpes simple PE20181531A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562245159P 2015-10-22 2015-10-22
US201562245031P 2015-10-22 2015-10-22
US201562247576P 2015-10-28 2015-10-28
US201562248252P 2015-10-29 2015-10-29

Publications (1)

Publication Number Publication Date
PE20181531A1 true PE20181531A1 (es) 2018-09-26

Family

ID=58558127

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000600A PE20181531A1 (es) 2015-10-22 2016-10-21 Vacuna del virus herpes simple

Country Status (19)

Country Link
US (2) US20180303929A1 (es)
EP (1) EP3365009A4 (es)
JP (2) JP2018536023A (es)
KR (1) KR20180096593A (es)
CN (1) CN108472355A (es)
AU (2) AU2016342049B2 (es)
BR (1) BR112018008090A2 (es)
CA (1) CA3002822A1 (es)
CL (1) CL2018001056A1 (es)
CO (1) CO2018005258A2 (es)
EA (1) EA201890999A1 (es)
IL (1) IL258833A (es)
MA (1) MA46024A (es)
MX (1) MX2018004918A (es)
PE (1) PE20181531A1 (es)
PH (1) PH12018500855A1 (es)
SG (1) SG11201803365RA (es)
TN (1) TN2018000155A1 (es)
WO (1) WO2017070623A1 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2015164674A1 (en) 2014-04-23 2015-10-29 Moderna Therapeutics, Inc. Nucleic acid vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
HK1256498A1 (zh) 2015-07-30 2019-09-27 Modernatx, Inc. 聚肽表位 rna
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
MD3386484T2 (ro) 2015-12-10 2022-11-30 Modernatx Inc Compoziții și metode de livrare a unor agenți terapeutici
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
WO2017201340A2 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
JP6983455B2 (ja) 2016-09-14 2021-12-17 モデルナティーエックス， インコーポレイテッド 高純度ｒｎａ組成物及びその調製のための方法
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
US20200054737A1 (en) * 2017-04-26 2020-02-20 Modema TX, Inc. Herpes simplex virus vaccine
EP3615060A4 (en) * 2017-04-26 2021-06-09 Merck Sharp & Dohme Corp. HSV ANTIGEN PEPTIDS AND HSV PROTEIN VACCINES
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
EP4242223A3 (en) * 2017-08-17 2024-03-13 The Trustees of The University of Pennsylvania Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
ES2983060T3 (es) 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN109701008B (zh) * 2019-02-18 2022-06-21 山东兴瑞生物科技有限公司 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法
CA3130888A1 (en) 2019-02-20 2020-08-27 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
JP2022526089A (ja) 2019-03-11 2022-05-23 モデルナティエックス インコーポレイテッド 流加バッチインビトロ転写プロセス
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
US20220280636A1 (en) * 2019-07-19 2022-09-08 Merck Sharp & Dohme Corp. Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof
KR20220035457A (ko) * 2019-07-21 2022-03-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 치료 바이러스 백신
WO2021197589A1 (en) * 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
TWI860474B (zh) 2020-04-22 2024-11-01 德商拜恩迪克公司 冠狀病毒疫苗
CN115803333A (zh) 2020-07-02 2023-03-14 生命技术公司 三核苷酸帽类似物、其制备和用途
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4304641A1 (en) * 2021-03-11 2024-01-17 Redbiotec AG Vaccine compositions and methods for treating hsv
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
EP4395748A1 (en) 2021-09-03 2024-07-10 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
IL314324A (en) * 2022-01-27 2024-09-01 BioNTech SE Pharmaceutical preparations for administration of herpes simplex virus antigens and related methods
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
WO2024131664A1 (zh) * 2022-12-19 2024-06-27 南京奥罗生物科技有限公司 单纯疱疹病毒疫苗及其应用
WO2024163465A1 (en) 2023-01-30 2024-08-08 Modernatx, Inc. Epstein-barr virus mrna vaccines
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024215721A1 (en) 2023-04-10 2024-10-17 Modernatx, Inc. Lyme disease vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025030097A2 (en) * 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025171082A1 (en) * 2024-02-06 2025-08-14 Board Of Regents, The University Of Texas System Prefusion-stabilized hsv2 gb proteins

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1993001301A1 (en) * 1991-07-05 1993-01-21 The Penn State Research Foundation Mutant antiviral regulatory proteins
GB9406498D0 (en) * 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
US7094767B2 (en) * 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
EP0948508A4 (en) * 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
TR200200838T2 (tr) * 1999-09-30 2002-06-21 University Of Washington İmmunolojik olarak önemli herpes simpleks virüs antijenleri.
AU7542301A (en) * 2000-06-09 2001-12-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes<sup>TM</sup>) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
ES2344078T3 (es) 2001-06-05 2010-08-17 Curevac Gmbh Arnm estabilizado con un contenido de g/c aumentado para la terapia genetica.
EP1412065A2 (en) 2001-07-27 2004-04-28 President And Fellows Of Harvard College Laminar mixing apparatus and methods
EP1443905A4 (en) 2001-10-03 2010-06-23 Univ Johns Hopkins COMPOSITIONS FOR ORAL GENE THERAPY AND METHOD OF USE THEREOF
AU2003217531A1 (en) 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
KR20060130057A (ko) * 2003-11-21 2006-12-18 알자 코포레이션 절단가능한 ｐｅｇ 표면 변형을 갖는 리포좀-ｄｎａ복합체에 의해 매개되는 유전자 송달
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US8241670B2 (en) 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
US8354476B2 (en) 2004-12-10 2013-01-15 Kala Pharmaceuticals, Inc. Functionalized poly(ether-anhydride) block copolymers
JP4390845B2 (ja) 2005-04-01 2009-12-24 インテザイン テクノロジーズ， インコーポレイテッド 薬物送達のためのポリマーミセル
EP1885403B1 (en) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
WO2006138572A2 (en) 2005-06-16 2006-12-28 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2007070705A2 (en) * 2005-12-15 2007-06-21 The Trustees Of The University Of Pennsylvania Cationic lipid-mediated vectors
US8309680B2 (en) 2006-02-21 2012-11-13 Nektar Therapeutics Segmented degradable polymers and conjugates made therefrom
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
CN101489589A (zh) * 2006-05-19 2009-07-22 沃尔特及伊莱萨霍尔医学研究院 免疫原性组合物
WO2008011609A2 (en) * 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
ATE498393T1 (de) 2006-09-08 2011-03-15 Univ Johns Hopkins Zusammensetzungen zur transportintensivierung durch die schleimhaut
EP2120859B1 (en) 2006-12-21 2013-11-20 Stryker Corporation Sustained-release formulations comprising bmp-7 crystals
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2644192B1 (en) 2007-09-28 2017-05-10 Pfizer Inc Cancer Cell Targeting Using Nanoparticles
WO2010005721A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
JP2012501966A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法
HUE035770T2 (en) 2008-06-16 2018-05-28 Pfizer Process for the preparation of diblock copolymers functionalized with targeting material for use in the preparation of therapeutic nanoparticles
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
WO2010030763A2 (en) 2008-09-10 2010-03-18 Bind Biosciences, Inc. High throughput fabrication of nanoparticles
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
JP5622254B2 (ja) 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
US8287910B2 (en) 2009-04-30 2012-10-16 Intezyne Technologies, Inc. Polymeric micelles for polynucleotide encapsulation
JP5823405B2 (ja) 2009-11-04 2015-11-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア 核酸含有脂質粒子および関連方法
EA201290498A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
JP6175237B2 (ja) 2009-12-15 2017-08-02 ファイザー・インク コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2012082165A1 (en) 2010-01-24 2012-06-21 Novartis Ag Irradiated biodegradable polymer microparticles
WO2011106607A2 (en) * 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
US20130196948A1 (en) 2010-06-25 2013-08-01 Massachusetts Insitute Of Technology Polymers for biomaterials and therapeutics
PT2590676T (pt) * 2010-07-06 2016-11-04 Glaxosmithkline Biologicals Sa Partículas de transferência de tipo virião para moléculas de arn auto-replicante
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP4098324A1 (en) * 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
EA201390600A1 (ru) 2010-10-22 2013-09-30 Байнд Терапьютикс, Инк. Терапевтические наночастицы с сополимерами с большим молекулярным весом
AU2011323250B2 (en) 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
CA2826199A1 (en) * 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2012109121A1 (en) 2011-02-07 2012-08-16 Purdue Research Foundation Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
AU2012237262A1 (en) 2011-03-31 2013-11-14 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
AU2012237260A1 (en) 2011-03-31 2013-11-14 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
EP4115876A1 (en) * 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
WO2013012476A2 (en) 2011-07-21 2013-01-24 Arizona Chemical Company, Llc Branched polyether-polyamide block copolymers and methods of making and using the same
HK1199736A1 (en) 2011-08-26 2015-07-17 箭头研究公司 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US8889657B2 (en) 2011-08-31 2014-11-18 Mallinckrodt Llc Nanoparticle PEG modification with H-phosphonates
EP2747761A1 (en) 2011-09-22 2014-07-02 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
CN104105504A (zh) * 2011-10-11 2014-10-15 诺华股份有限公司 重组多顺反子核酸分子
CA2852917C (en) 2011-10-18 2020-07-07 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
CN104136419B (zh) 2011-10-27 2017-11-03 麻省理工学院 能够形成药物封装微球的在n末端上官能化的氨基酸衍生物
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
PT2791160T (pt) * 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
WO2013113326A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2809702B1 (en) 2012-02-03 2017-12-20 Rutgers, The State University of New Jersey Polymeric biomaterials derived from phenolic monomers and their medical uses
WO2013120052A1 (en) 2012-02-10 2013-08-15 E. I. Du Pont De Nemours And Company Preparation, purification and use of high-x diblock copolymers
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
JP6189415B2 (ja) * 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
ES2864878T5 (es) * 2012-06-08 2024-10-23 Translate Bio Inc Administración pulmonar de ARN, a células objetivo no pulmonares
WO2014093924A1 (en) * 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
EP2929035A1 (en) * 2012-12-07 2015-10-14 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
US10087247B2 (en) * 2013-03-14 2018-10-02 Translate Bio, Inc. Methods and compositions for delivering mRNA coded antibodies
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
ES2967701T3 (es) * 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
TW201534578A (zh) * 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
WO2015164674A1 (en) * 2014-04-23 2015-10-29 Moderna Therapeutics, Inc. Nucleic acid vaccines
WO2018226638A1 (en) * 2017-06-05 2018-12-13 The Brigham And Women's Hospital, Inc. Vero cell lines stably expressing hsv icp0 protein

Also Published As

Publication number Publication date
BR112018008090A2 (pt) 2018-11-13
AU2016342049B2 (en) 2023-05-18
CN108472355A (zh) 2018-08-31
JP2018536023A (ja) 2018-12-06
EA201890999A1 (ru) 2018-12-28
TN2018000155A1 (en) 2019-10-04
KR20180096593A (ko) 2018-08-29
MA46024A (fr) 2019-07-03
EP3365009A4 (en) 2019-07-03
SG11201803365RA (en) 2018-05-30
WO2017070623A1 (en) 2017-04-27
AU2023216825A1 (en) 2023-09-07
JP2022037134A (ja) 2022-03-08
AU2016342049A1 (en) 2018-06-07
CO2018005258A2 (es) 2018-11-22
IL258833A (en) 2018-06-28
US20180303929A1 (en) 2018-10-25
US20240173400A1 (en) 2024-05-30
EP3365009A1 (en) 2018-08-29
CL2018001056A1 (es) 2018-10-19
PH12018500855A1 (en) 2018-10-29
MX2018004918A (es) 2019-04-01
CA3002822A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
PE20181531A1 (es) Vacuna del virus herpes simple
PE20181530A1 (es) Vacuna de virus sincitial respiratorio
CY1125368T1 (el) Εμβολια κατα των ιων του αναπνευστικου συστηματος
BR112018008078A2 (pt) vacina de vírus influenza de amplo espectro
PE20181529A1 (es) Vacunas de acido nucleico para el virus varicela-zoster (vzv)
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
NI201700128A (es) Composiciones de acido obeticolico y metodos de uso.
BR112016024644A2 (pt) vacinas de ácido nucleico
MX368655B (es) Variantes de glucoamilasa y polinucleótidos que las codifican.
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
MX2021010060A (es) Produccion de virus en huevos aviares.
BR112016018654A2 (pt) Composições de silicato estabilizadas e seu uso como composições antiperspirantes
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos
CL2021001708A1 (es) Métodos para formar poliplejos
DK2921171T3 (da) Oftalmiske, intraartikulære eller intravesikale præparater indeholdende n-acyl-ethanolaminer
AR106464A1 (es) Vacuna de virus sincitial respiratorio
AR105431A1 (es) Vacunas para enfermedades infecciosas
AR102161A1 (es) Procesos para preparar 2,5-diclorofenol
TH1601002827B (th) ระบบการให้วัคซีนสำหรับทำการจัดส่งวัคซีนไปยังสัตว์ปีกประเภทไก่วัยรุ่นเพศเมีย และวิธีการ, อุปกรณ์ และชุดประกอบที่เกี่ยวเนื่อง
TH148817B (th) รีคอมบิแนนท์ไวรัสเริมของนกชนิดมัลติวาเลนต์ และวัคซีนเพื่อสร้างภูมิคุ้มกันสำหรับสปีชีส์ของนก